戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 c-Jun and activating transcription factor 2 (ATF2).
2 tion of an AP1 complex (containing c-Jun and ATF2).
3 phospho-CREB and cytoplasmic accumulation of ATF2.
4  inhibited JNK activity via competition with ATF2.
5 or ATP and noncompetitive inhibition against ATF2.
6 l of the basic region leucine zipper protein ATF2.
7  targets the transcription factors c-Jun and ATF2.
8 ased levels of the histone acetyltransferase ATF2.
9 ncluding the transcription factors c-Jun and ATF2.
10 and requires transcription factors c-Jun and ATF2.
11  phosphorylation of the transcription factor ATF2.
12 y blocked by ATF2DeltaN, a dominant negative ATF2.
13 t binds transcription factors c-Jun and CREB/ATF2.
14 de derived from amino acid (aa) 51 to 100 of ATF2.
15 ion of the AP-1-related transcription factor ATF2.
16 vated protein (MAP) kinase and its substrate ATF2.
17 yclase, ADCY8, and the transcription factor, ATF2.
18 horylation and transcriptional activation of ATF2.
19 , a transcription factor homologous to human ATF2.
20 r63 and Ser73 of c-Jun or Thr69 and Thr71 of ATF2.
21 lates and activates the transcription factor ATF2.
22 IL-23p19 indirectly, likely via reduction of ATF2.
23 y regulates the transcriptional potential of ATF2.
24 effectively influenced protein expression of ATF2.
25  is maintained through the JNK activation of ATF2.
26 ed on the delta-domain sites of JIP ( 3) and ATF2 ( 1) were not recognized by p38, also of the MAPK f
27                                Expression of ATF2(150-248) in fibroblasts or melanoma but not in ATF2
28                   Constitutive expression of ATF2(150-248) peptide outcompeted TIP49b interaction wit
29 and requires amino acids 150 to 248 of ATF2 (ATF2(150-248)), which are implicated in intramolecular i
30 able of processing natural protein substrate ATF2; 172 site phosphorylation did not.
31                         Phosphoantibodies to ATF2(490/8) reveal dose- and time-dependent phosphorylat
32                                 Furthermore, ATF2(50-100) binds to c-Jun N-terminal kinase (JNK) and
33                     Here we demonstrate that ATF2(50-100) induced apoptosis by sequestering ATF2 to t
34   Mutations within the JNK binding region of ATF2(50-100) or expression of TAM67 or JunD RNAi attenua
35                              Mutation within ATF2(50-100) that impairs association with JNK and the i
36 s sensitization of melanoma cells expressing ATF2(50-100) to apoptosis after treatment with anisomyci
37 and B16F10 mouse melanomas were inhibited by ATF2(50-100) to varying degrees up to a complete regress
38 peptide spanning amino acids 50-100 of ATF2 (ATF2(50-100)) reduces ATF2 transcriptional activities wh
39 ived from activating transcription factor 2 (ATF2(50-100)).
40 NA interference (RNAi) reduces the degree of ATF2(50-100)-induced apoptosis.
41 s inhibition of melanoma's tumorigenicity by ATF2(50-100).
42 ed (+/-250 bp) with RUNX3 (64%), BATF (55%), ATF2 (51%), IRF4 (41%), MEF2A (35%), PAX5 (34%), SPI1 (2
43              Here we show that expression of ATF2((51-100)) in human melanoma cells reduced their gro
44                         In addition, loss of ATF2/7 desensitises Emu-Myc lymphoma cells to spontaneou
45      Despite the delayed p38MAPK activation, ATF2, a substrate of p38MAPK, is still phosphorylated, l
46                                Knock down of ATF2 abolished TA-induced ATF3 expression.
47                         Targeted mutation of ATF2 abrogates both constitutive and inducible expressio
48                           Formation of c-JUN-ATF2-activated heterodimers was increased after AA limit
49                        Transcription factors ATF2 (activating transcription factor 2) and ATF7 (activ
50 splenic tumors, controlled the expression of ATF2 (activating transcription factor 2).
51                        Reduced or heightened ATF2 activity also sensitizes or desensitizes cells to E
52 nt with this concept, the phosphorylation of ATF2 along with the expression and phosphorylation of c-
53 se in transcriptional activity by endogenous ATF2 and a markedly increased sensitivity to the four ag
54  peptide outcompeted TIP49b interaction with ATF2 and alleviated the suppression of ATF2 transcriptio
55  c-MYC induces stress-mediated activation of ATF2 and ATF7 and that these transcription factors regul
56              The B cell-specific deletion of ATF2 and ATF7 in mice results in significantly accelerat
57 ism for JNK1beta1 with transcription factors ATF2 and c-Jun along with interaction kinetics for these
58                                              ATF2 and c-Jun are key components of activating protein-
59                                         Both ATF2 and c-Jun interact with a novel enhancer in the int
60    Together, these findings demonstrate that ATF2 and c-Jun mutually regulate each other by altering
61  immunoprecipitation with antibodies against ATF2 and c-Jun or their phosphorylated forms and hybridi
62                                     K(m) for ATF2 and c-Jun was 1.1 and 2.8 muM, respectively.
63 nse occurs at least partly via activation of ATF2 and c-Jun, leading to large-scale coordinate gene e
64 e affinity of unphosphorylated JNK1beta1 for ATF2 and c-Jun, to 0.80 +/- 0.04 versus 0.65 +/- 0.07 mu
65 rgistically activated promoter activity with ATF2 and c-Jun.
66                 The induction is mediated by ATF2 and c-Jun.
67  and activation of AP-1 components including ATF2 and c-Jun.
68  promoters are bound upon phosphorylation of ATF2 and c-Jun.
69 ibited pure noncompetitive inhibition versus ATF2 and competitive inhibition versus ATP.
70 ssion of the downstream transcription factor ATF2 and completely blocked by ATF2DeltaN, a dominant ne
71 on leads to the decreased phosphorylation of ATF2 and consequent increased expression of the melanocy
72 or-activated receptor-gamma accompanied with ATF2 and CREB (cAMP-response element-binding protein) wa
73 e and activate the two transcription factors ATF2 and Elk-1.
74                 Moreover, shRNA silencing of ATF2 and FoxP3 reveals an important role of ATF2-FoxP3 p
75        Significantly, a reduction of nuclear ATF2 and increased beta-catenin expression were seen in
76                        Conversely, cytosolic ATF2 and induction of IFNbeta1 coincides with therapeuti
77  c-Jun in the nucleus prevents the export of ATF2 and is essential for the transcriptional activation
78 symmetrically located amino acid residues in ATF2 and Jun facilitated the interactions between hetero
79                         Different regions of ATF2 and Jun mediated their orientation-dependent transc
80                             Notably, nuclear ATF2 and low expression of IFNbeta1 in melanoma tumor sa
81 on and Mkk4(-/-) ESCs exhibited diminished p-ATF2 and MEF2C expression, resulting in impaired MHC ind
82 creased expression of c-JUN was dependent on ATF2 and on activation of the MEK-ERK and JNK arms of th
83 perturbation resulted in the accumulation of ATF2 and RNF20 and the promiscuous accumulation of DDR-a
84 A and protein expression of c-Fos, c-Jun and ATF2 and sustained repression of Fra-2.
85 ctly upregulating gene expression (c-fos and ATF2) and by activating pathways that stimulate AP-1 act
86 oteins (c-Jun dimerization protein 2 [JDP2], ATF2, and histone deacetylase 6 [HDAC6]), as determined
87 d elevated phosphorylation of MKK4, p38, and ATF2, and increased MEF2C expression.
88 tion of interferon response factor 3 (IRF3), ATF2, and NF-kappaBp65.
89 causes activation of calcineurin (Cn), NFAT, ATF2, and NFkappaB/Rel factors, which collectively alter
90 hat cAMP acts through the PKA/CREB, PKA/PI3K/ATF2, and PKA/ERK/ATF2 pathways to control a key vascula
91                                 Thus, c-Jun, ATF2, and TCFs are required to connect the intracellular
92 F2DeltaN), increases activities of p38 MAPK, ATF2, and the level of TNFalpha expression.
93 cells by activating transcription of c-Jun-, ATF2-, and TCF-controlled genes.
94 Although it has been believed that c-Jun and ATF2 are constitutively localized in the nucleus, where
95 ansport (e.g. QDR2, YBT1), lipid metabolism (ATF2, ARE1), cell stress (HSP12, CTA1), DNA repair (YIM1
96 -driven mouse B-cell lymphomas, we find that ATF2 as well as MAP kinase c-Jun N-terminal kinase (JNK)
97                                              ATF2 association with TIP60 on chromatin is decreased fo
98 ed ATF2 phosphorylation and increased TIP49b-ATF2 association.
99 ndent and requires amino acids 150 to 248 of ATF2 (ATF2(150-248)), which are implicated in intramolec
100  of a peptide spanning amino acids 50-100 of ATF2 (ATF2(50-100)) reduces ATF2 transcriptional activit
101                     We demonstrate here that ATF2, ATF3, and ATF4 are each robustly induced in the nu
102        Because amphetamine and stress induce ATF2, ATF3, and ATF4 in nucleus accumbens, and overexpre
103           siRNA-based depletion of c-Jun and ATF2 attenuated TNFalpha action on Map4k4 mRNA expressio
104           Activating transcription factor 2 (ATF2) belongs to the basic leucine zipper family of tran
105 d kinase inhibitors down-regulated Thr(P)-71-ATF2 binding to the il23a promoter and il23a mRNA expres
106 K, and p38 MAPK inhibitors blunted Thr(P)-69-ATF2 binding.
107 Thr(P)-69-activating transcription factor 2 (ATF2) binding in response to zymosan.
108 fied this region as a core sequence to which ATF2 binds.
109                                   Similarly, ATF2 bound to opposite half-sites in Fos-ATF2-NFAT1 and
110 l mobility shift assays revealed that mainly ATF2 bound to this CRE-like element, and mutation of the
111  dose- and time-dependent phosphorylation of ATF2 by ATM that results in its rapid colocalization wit
112 rylations on N-terminal Thr-71 and Thr-69 of ATF2 by ERK and p38 MAPK, MEK, and p38 MAPK inhibitors b
113 ivation of nuclear factor-kappaB, c-jun, and ATF2 by TNF was comparable in HUAECs and HUVECs, whereas
114 ylated rapidly and this methylation inhibits ATF2/c-Jun and CREB transcription factor binding in vitr
115  that may mediate a repressor effect because ATF2 can heterodimerize with other bZIP molecules.
116             Jun dimerization with Fos versus ATF2 caused it to bind opposite half-sites at nonconsens
117 tions detected included HBZ with MAFB, MAFG, ATF2, CEBPG, and CREBZF and MEQ with NFIL3.
118  in the presence and absence of both ATP and ATF2 competitive inhibitors.
119 t or -deficient cells and requires the Smad1-Atf2 complex that facilitates their recruitment to the p
120           Activating transcription factor 2 (ATF2/CRE-BP1) is implicated in transcriptional control o
121  like the yeast GCN4, and the mammalian JUN, ATF2, CREB, C/EBP, and PAR leucine zippers, characterize
122 that control mitochondrial function, such as ATF2, CREB, PGC1alpha, DIO2, NRF1, CYTC, COX2, ATP5beta,
123 , as well as transcription factors including Atf2, Creb3l1, and Erg.
124                  One of these clones, termed ATF2 deletion (ATF2d), encodes a novel ATF2 isoform and
125 creased cellular survival and revealed c-Jun/ATF2-dependent control of ATF3 expression.
126 insight into regulation of ATM activation by ATF2-dependent control of TIP60 stability and activity.
127 st explained through coordinated kappaB- and ATF2-dependent transcription; and (iii) il23a expression
128 ), and strongly increase phosphorylation and ATF2-dependent transcriptional activity.
129 ific combinations of c-Jun, CREB1, ATF1, and ATF2 dimers.
130 ly, stable expression of a dominant negative ATF2 (dnATF2) quantitatively blocks phosphorylation of e
131                     The transcription factor ATF2 elicits oncogenic activities in melanoma and tumor
132                                  The p38/JNK-ATF2/Elk-1bifan synchronizes the output of activated tra
133 toxic stress attenuates PKCepsilon effect on ATF2; enables ATF2 nuclear export and localization at th
134                      Moreover, the wild type ATF2-expressing clones exhibited rapid DNA repair after
135                   Importantly, inhibition of ATF2 expression by small interfering RNA in CD4(+) cells
136                                Inhibition of ATF2 expression decreased recruitment of Mre11 to IRIF,
137 anoma, we evaluated the pattern and level of ATF2 expression in a large cohort of melanoma specimens.
138                                Inhibition of ATF2 expression in these lines restored TIP60 protein le
139 elanoma and prostate cancer cell lines whose ATF2 expression is inversely correlated with TIP60 level
140                 The clinical significance of ATF2 expression is unknown.
141                               Strong nuclear ATF2 expression was associated with metastatic specimens
142                           Strong cytoplasmic ATF2 expression was associated with primary specimens ra
143  However, activating transcription factor-2 (ATF2) expression was significantly lower in CD8(+) compa
144 nt with these findings, keratinocytes of K14.ATF2(f/f) mice exhibit greater anchorage-independent gro
145                            Papillomas of K14.ATF2(f/f) mice exhibit reduced expression of presenilin1
146 2-tetradecanoate 13-acetate (DMBA/TPA)], K14.ATF2(f/f) mice showed significant increases in both the
147 expressed ATF2 mutant with K14-Cre mice (K14.ATF2(f/f)) resulted in selective expression of mutant AT
148 2 were poor substrates relative to c-Jun and ATF2 for active recombinant JNK1.
149 duced p19 promoter activation, and c-Jun and ATF2 formed a protein complex, demonstrated by co-immuno
150  ATF2 and FoxP3 reveals an important role of ATF2-FoxP3 pathway in the anisomycin-induced apoptosis o
151 CREB) and activating transcription factor 2 (ATF2), function as a transcriptional activator and a rep
152 sistent with this, both Gal4-c-Jun- and Gal4-ATF2-fusion proteins were activated by RalA signalling t
153 on factor activating transcription factor 2 (ATF2) has been shown to be associated with melanocytic o
154                                        c-Jun-ATF2 heterodimers activate the expression of many target
155 fibre bundles and that of ERK1/2, RSK1/2 and ATF2 in both fibre types.
156               We conclude that inhibition of ATF2 in concert with increased JNK/Jun and JunD activiti
157                         Stable expression of ATF2 in human breast carcinoma BT474 cells increases tra
158  insight into the pathophysiological role of ATF2 in human diseases.
159  = 25 +/- 6 nM) competitive inhibitor versus ATF2 in JNK3alpha1.
160 e CREB or a constitutively nuclear-localized ATF2 in LNCaP cells inhibits IR-induced NE-like differen
161         To determine the prognostic value of ATF2 in melanoma, we evaluated the pattern and level of
162  thereby indicating a suppressor activity of ATF2 in skin tumor formation.
163             Our findings identify a role for ATF2 in the DNA damage response that is uncoupled from i
164 d transformation and reveal a novel role for ATF2 in the inhibition of the Ras-Raf-MEK-ERK signaling
165 nditions, activating transcription factor-2 (ATF2) in cooperation with Cul3 ubiquitin ligase promotes
166 ctions of activating transcription factor-2 (ATF2) in the development and therapeutic resistance of m
167 vealed a positive feedback mechanism whereby ATF2 induces p38 MAPK phosphorylation to further induce
168 O80 chromatin-remodeling complex, as a novel ATF2-interacting protein.
169 in consisting of HIV-TAT and aa 51 to 100 of ATF2 into SW1 melanomas efficiently inhibits their growt
170              We previously demonstrated that ATF2 is a nucleocytoplasmic shuttling protein, and it co
171              Although elevated expression of ATF2 is also required for v-Rel-mediated transformation,
172                                              ATF2 is among transcription factors implicated in the pr
173               The transcription potential of ATF2 is enhanced markedly by NH2-terminal phosphorylatio
174 l findings in which transcriptionally active ATF2 is involved in tumor progression-proliferation in m
175                                      Nuclear ATF2 is likely to be transcriptionally active, whereas c
176                    TIP49b's association with ATF2 is phosphorylation dependent and requires amino aci
177                        Activation of Jun and ATF2 is severely diminished in Bmp7-null kidneys, provid
178       The activating transcription factor 2 (ATF2) is a member of the ATF/cAMP-response element-bindi
179           Activating transcription factor 2 (ATF2) is regulated by JNK/p38 in response to stress.
180 ermed ATF2 deletion (ATF2d), encodes a novel ATF2 isoform and was chosen for further characterization
181 n proposed to require a fixed orientation of ATF2-Jun binding.
182                        Our results show that ATF2-Jun heterodimers bound IFNb in both orientations al
183                                              ATF2-Jun heterodimers that bound IFNb in opposite orient
184 FNb in association with both orientations of ATF2-Jun heterodimers with the same cooperativity.
185                                              ATF2-Jun, IRF3, and HMGI recognize a composite regulator
186                                  Cooperative ATF2-Jun-IRF3 complex formation at IFNb has been propose
187 to opposite half-sites in Fos-ATF2-NFAT1 and ATF2-Jun-NFAT1 complexes.
188  increased after AA limitation, and c-JUN or ATF2 knockdown suppressed the induction of c-JUN and oth
189             ATF2d retains the bZIP domain of ATF2, lacks the N-terminal zinc-finger region, and inclu
190 atively blocks phosphorylation of endogenous ATF2 leading to a marked decrease in transcriptional act
191           TGFbeta enhanced the activation of ATF2, leading to increased phospho-ATF2 levels within th
192 vation of ATF2, leading to increased phospho-ATF2 levels within the DNA-protein complexes.
193 t transcription required the presence of the ATF2-like AP1-site at -70 bp and the c-Jun binding motif
194 eletion causes a frame shift, resulting in a ATF2-like polypeptide of approximately 60 kDa.
195       A favorable prognosis was predicted by ATF2 ln(non-nuclear/nuclear AQUA score ratio) of more th
196 ere is a sub-population of Her2(+)p-p38(lo)p-Atf2(lo)Twist1(hi)E-cad(lo) early cancer cells that is i
197 ein kinase C-varepsilon (PKCvarepsilon)- and ATF2-mediated mechanism that facilitates resistance by t
198 f PKCvarepsilon with chemotherapies relieves ATF2-mediated transcriptional repression of IFNbeta1, re
199 f papilloma development compared with the WT ATF2 mice.
200          Moreover, our findings suggest that ATF2 might be a useful prognostic marker in early-stage
201                                 Knockdown of atf2 mRNA with siRNA correlated with inhibition of il23a
202                                  Relative to ATF2 mRNA, this clone contains an internal 97-nt deletio
203      In addition, a phosphorylation-negative ATF2 mutant construct decreased basal and TGFbeta-mediat
204         Crossing the conditionally expressed ATF2 mutant with K14-Cre mice (K14.ATF2(f/f)) resulted i
205 ors, JUN, activating transcription factor 2 (ATF2), myocyte-specific enhancer factor 2A (MEF2A), and
206 ly, ATF2 bound to opposite half-sites in Fos-ATF2-NFAT1 and ATF2-Jun-NFAT1 complexes.
207 eighbored genes associated with SCZ (NOS1AP, ATF2, NSF, and PIK3C3).
208 PKCepsilon, as seen in melanoma cells, block ATF2 nuclear export and function at the mitochondria, th
209 ttenuates PKCepsilon effect on ATF2; enables ATF2 nuclear export and localization at the mitochondria
210 a is determined by PKCepsilon, which directs ATF2 nuclear localization.
211 0-248) in fibroblasts or melanoma but not in ATF2-null cells caused a profound G(2)M arrest and incre
212                         Although analysis of Atf2-null NK cells shows no defect, the transgenic mice
213 tly, c-Jun-dependent nuclear localization of ATF2 occurs during retinoic acid-induced differentiation
214  the p38alpha transcription factor substrate ATF2 occurs in a precise sequence.
215 e that the protein kinase ATM phosphorylates ATF2 on serines 490 and 498 following ionizing radiation
216 n relies on complementary phosphorylation of ATF2 on Thr-69 and Thr-71 dependent on PKC and MAPK acti
217 tanding how subcellular localization enables ATF2 oncogenic or tumor suppressor functions.
218                            Inhibiting either ATF2 or Cul3 expression by small interfering RNA stabili
219  expression of a dominant-negative mutant of ATF2 or expression of an ATF2-specific short hairpin RNA
220               Individual silencing of c-Jun, ATF2, or ATF3 decreased cellular survival and revealed c
221 ot alter the expression of CREB, CREM, ATF1, ATF2, or ATF4 proteins.
222 l activation through c-Jun but not the ATF1, ATF2, or CREB transcription factor.
223 hese results, overexpression of c-Jun, ATF1, ATF2, or CREB1 in transiently transfected osteoblastic c
224 nhibition, whereas transfection of Creb1 and Atf2 overexpression constructs enhanced cAMP-driven Cd39
225 g viral-mediated gene transfer, we show that ATF2 overexpression in nucleus accumbens produces increa
226 ympathetic stimulation through the cAMP-CREB/ATF2 pathway.
227  morphogenetic protein-Smad1 and Atm-p38MAPK-Atf2 pathways in p53-proficient or -deficient cells and
228 ugh the PKA/CREB, PKA/PI3K/ATF2, and PKA/ERK/ATF2 pathways to control a key vascular homeostatic medi
229  mechanisms underlying the activities of the ATF2 peptide while highlighting its possible use in drug
230                 Peptide inhibitors from both ATF2 (peptide 1) and JNK-interacting protein 1 (JIP-1) (
231 rom the phosphoacceptor activation domain on ATF2 (peptides 4 and 5) were recognized neither as subst
232 he first time in VSMC that TGFbeta activates ATF2 phosphorylation and Csrp2 gene expression via a CRE
233 tivation of p38 kinase, all of which induced ATF2 phosphorylation and increased TIP49b-ATF2 associati
234      TA treatment resulted in an increase in ATF2 phosphorylation, which was followed by a subsequent
235 equential nature of the JNK2alpha2 catalyzed ATF2 phosphorylation.
236 c-Jun and activating transcription factor-2 (ATF2) phosphorylation and binding to the PI.3/PII region
237 dicate that JNK-dependent phosphorylation of ATF2 plays an important role in the drug resistance phen
238                            Here we show that ATF2 possesses a nuclear export signal in its leucine zi
239 ranscriptionally active, whereas cytoplasmic ATF2 probably represents an inactive form.
240  factor IRF3, and activator of transcription ATF2, reaching levels similar to those seen in C(ko) vir
241                                              ATF2 regulates target gene expression by binding to the
242           Activating transcription factor 2 (ATF2) regulates transcription in response to stress and
243                    Investigating the mode of ATF2 regulation revealed a positive feedback mechanism w
244 resistance of melanoma via the PKCvarepsilon-ATF2 regulatory axis.
245                    The activation of the JNK-ATF2 reporter was mediated by the DEP domain of Dishevel
246 lts suggest that cytoplasmic localization of ATF2 requires function of at least one of the NESs.
247                                              ATF2 requires neither JNK/p38 nor its DNA binding domain
248                            Overexpression of ATF2 resulted in significant increase in ATF3 promoter a
249 H(2)-terminal kinase with c-Jun but not with ATF2, resulting in concomitant increase in TRE-mediated
250 a peptide that corresponds to aa 51 to 60 of ATF2 sensitizes melanoma cells to spontaneous apoptosis,
251 led the induction was mediated by a p38-MAPK-ATF2 signaling pathway and that RNAi-mediated inhibition
252                              Elevated Mapk14-Atf2 signaling predicted poor response to sorafenib ther
253 g Mapk14-dependent activation of Mek-Erk and Atf2 signaling.
254 -negative mutant of ATF2 or expression of an ATF2-specific short hairpin RNA interfered with TRPM3-me
255 had both weak cytoplasmic and strong nuclear ATF2 staining had the worst outcome, both among the full
256 their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL re
257                                        Thus, ATF2 subcellular localization is probably modulated by m
258  cancer cells, suggesting that alteration of ATF2 subcellular localization may be involved in the pat
259 d further understanding of the regulation of ATF2 subcellular localization under various pathological
260 ntial kinetic mechanism and that the ATP and ATF2 substrate sites were non-interacting.
261 sphorylation by MKK6, kinase activity toward ATF2 substrate, thermal stability, and X-ray crystal str
262 ir transcription factor substrates c-Jun and ATF2, suggesting that D-site-containing substrates also
263 NES enhances the transcriptional activity of ATF2, suggesting that the novel NES negatively regulates
264 d JNK2-mediated phosphorylation of c-Jun and ATF2, suggesting that transcription factors, MKK4, and t
265    Furthermore, co-transfection of c-Jun and ATF2 synergistically induced p19 promoter activation, an
266                                Inhibition of ATF2 target gene expression via expression of a dominant
267 is associated with transgenic insertion into Atf2, the gene for the basic leucine zipper (bZIP) trans
268  the phosphorylation of CREB1 (Ser(133)) and ATF2 (Thr(71)) in a PKA-, PI3K-, and ERK-dependent fashi
269  of CREB, transcription factor 1 (ATF1), and ATF2, three transcription factors that bind to the cycli
270 a shift in the K(D) of the active kinase for ATF2 to 1.70 +/- 0.25 muM and for c-Jun of 3.50 +/- 0.95
271 ta1 decreased the affinity of the kinase for ATF2 to 11.0 +/- 1.1 muM and for c-Jun to 17.0 +/- 7.5 m
272 ted that binding of phosphorylated CREB1 and ATF2 to cAMP-response element-like sites was significant
273                               The ability of ATF2 to reach the mitochondria is determined by PKCepsil
274 F2(50-100) induced apoptosis by sequestering ATF2 to the cytoplasm, thereby inhibiting its transcript
275 f the c-JUN gene by recruitment of c-JUN and ATF2 to two AP-1 sites within the proximal promoter.
276 g through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) respon
277                                 Furthermore, ATF2-transactivated Csrp2 promoter activity and TGFbeta
278            Finally, we identified a putative Atf2 transcription factor, which is required for APP1 tr
279 tors resulting in phosphorylation of Jun and ATF2 transcription factors.
280                  Altering the balance of Jun/ATF2 transcriptional activities sensitized melanoma cell
281  expression of TIP49b efficiently attenuated ATF2 transcriptional activities under normal growth cond
282  acids 50-100 of ATF2 (ATF2(50-100)) reduces ATF2 transcriptional activities while increasing the exp
283 e implicated in intramolecular inhibition of ATF2 transcriptional activities.
284  with ATF2 and alleviated the suppression of ATF2 transcriptional activities.
285                 Our data reveal that loss of ATF2 transcriptional activity serves to promote skin tum
286 e transgenic mice express abnormal truncated Atf2 transcripts that may mediate a repressor effect bec
287                       Here, we identify that ATF2 tumor suppressor function is determined by its abil
288 c-jun and activating transcription factor 2 (ATF2) upon activation by a variety of stress-based stimu
289                                Inhibition of ATF2 via RNA interference likewise increased c-Jun expre
290                  Cytoplasmic localization of ATF2 was observed in melanoma, brain tissue from patient
291          Here, we use a mouse model in which ATF2 was selectively deleted in keratinocytes.
292                                              ATF2 was significantly increased in the same group.
293 tes JNK, which then phosphorylates c-Jun and ATF2 when bound to the c-jun promoter.
294 ite in the dp5 promoter that binds c-Jun and ATF2, which is critical for dp5 promoter induction after
295 ways are mediated through phosphorylation of ATF2, which is mediated by p38 MAPK-, JNK- and ERK-depen
296 ha1 activity in a competitive fashion versus ATF2 while being pure noncompetitive toward ATP.
297 wed that unphosphorylated JNK1beta1 bound to ATF2 with similar affinity as it did to c-Jun (K(D) = 2.
298 f JNK-dependent transcription factors (c-Jun/ATF2) with activated IRF3 in the induction of primary IR
299 ) resulted in selective expression of mutant ATF2 within the basal layer of the epidermis.
300 r anchorage-independent growth compared with ATF2 WT keratinocytes.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top